Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × COVID-19 × Observation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 7 Leukemia, Myeloid, Acute 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Neoplasms 3 Sarcoma 2 Oropharyngeal Neoplasms 2 Neuroblastoma 2 Melanoma 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Brain Neoplasms 2 Anus Neoplasms 2 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Intraepithelial Lesions 1 Smoldering Multiple Myeloma 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Pleuropulmonary blastoma 1 Pathologic Complete Response 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1

Interventions

tocilizumab 1 selinexor 1 lenzilumab 1 cilgavimab and tixagevimab drug combination 1 Standard of Care 1 Practice Guidelines as Topic 1 Observation 1 Interferon-alpha 1 Immunoglobulin G 1 IMM-101 1 Disulfides 1 CVnCoV COVID-19 vaccine 1 COVID-19 Vaccines 1 BNT162 Vaccine 1 2019-nCoV Vaccine mRNA-1273 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04442048 2025-12-30

COV-IMMUNO

Canadian Cancer Trials Group

Phase 3 Completed

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡